CONTENTS

COMMENTARY

Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise.
Dennis A. Smith and Malcolm Rowland ........................................... 665

MINIREVIEW

Overview of the Components of Cardiac Metabolism.
Elizabeth A. Hausner, Susan A. Elmore, and Xi Yang .................................. 673

ARTICLES

Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate–Peroxisome Proliferator–Activated Receptor-γ Activation.
Feng Xu, Liang Zhu, Chaoqun Qian, Junjie Zhou, Donghao Geng, Ping Li, Wenjing Xuan, Fangge Wu, Kaijing Zhao, Weimin Kong, Yuanyuan Qin, Limin Liang, Li Liu, and Xiaodong Liu ........................................... 556

Rolapitant Is a Reversible Inhibitor of CYP2D6.
Sarah M. Glass, Sabrina M. Leddy, Michael C. Orwin, Garret P. Miller, Kyle A. Furge, and Laura Lowe Furge ........................................... 567

Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity.
Yu-Jie Chen, Jian Zhang, Ping-Ping Zhu, Xian-Wen Tan, Qiu-Hong Lin, Wen-Xia Wang, Shan-Shan Yin, Ling-Zhi Gao, Ming-Ming Su, Chang-Xiao Liu, Liang Xu, Wei Jia, Irina F. Sverriouikova, and Ke Lan ........................................... 574

Maternal Plasma l-Carnitine Reduction During Pregnancy Is Mainly Attributed to OCTN2-Mediated Placental Uptake and Does Not Result in Maternal Hepatic Fatty Acid β-Oxidation Decline.
Mengru Bai, Qingquan Zeng, Yingchun Chen, Mingyang Chen, Ping Li, Zhiyuan Ma, Dongli Sun, Hui Zhou, Caihong Zheng, Su Zeng, and Huidi Jiang ........................................... 582

Developmental Expression of the Cytoplasmic Sulfotransferases in Human Liver.

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.

Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4.
Pramod C. Nair, Ross A. McKinnon, and John O. Miners ........................................... 616

Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.
Sayaka Deguchi, Tomoki Yamashita, Keisuke Igai, Kazuo Harada, Yukiko Toba, Kazumasa Hirata, Kazuo Takayama, and Hiroyuki Mizuguchi ........................................... 632

RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms.
Kaori Nozaki, Masataka Nakano, Chika Iwakami, Tatsuki Fukami, and Miki Nakajima ........................................... 639

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.
Philippe B. Pierrillas, Emilie Henin, Kathryn Ball, Julien Ogier, Magali Amiel, Laurence Kraus-Berthier, .... Continued on next page